Last reviewed · How we verify
CoronaVac Vaccine
CoronaVac is an inactivated SARS-CoV-2 vaccine that stimulates the immune system to produce antibodies and cellular immunity against the virus.
CoronaVac is an inactivated SARS-CoV-2 vaccine that stimulates the immune system to produce antibodies and cellular immunity against the virus. Used for Prevention of COVID-19 in adults and adolescents.
At a glance
| Generic name | CoronaVac Vaccine |
|---|---|
| Also known as | Sinovac |
| Sponsor | Clover Biopharmaceuticals AUS Pty |
| Drug class | Inactivated viral vaccine |
| Target | SARS-CoV-2 spike protein and other viral antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains chemically inactivated whole SARS-CoV-2 virions, which cannot cause infection but retain antigenic epitopes. Upon administration, these viral antigens are presented to the immune system, triggering both humoral (antibody) and cell-mediated immune responses. This prepares the body to recognize and neutralize live virus upon exposure.
Approved indications
- Prevention of COVID-19 in adults and adolescents
Common side effects
- Injection site pain or swelling
- Fatigue
- Myalgia
- Headache
- Fever
- Nausea
Key clinical trials
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Immunogenicity and Safety Study of SARS-CoV-2 DNA Vaccine (ICCOV) (PHASE2)
- Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine (PHASE4)
- Community-based Sero-epidemiological Study of COVID-19
- Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study
- Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older (PHASE3)
- Immunogenicity Induced by COVID-19 Vaccines in Mexican Population
- Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CoronaVac Vaccine CI brief — competitive landscape report
- CoronaVac Vaccine updates RSS · CI watch RSS
- Clover Biopharmaceuticals AUS Pty portfolio CI